ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

 News | News By Subject | News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Eli Lilly and Company (LLY) Drug Chosen for Alzheimer's Prevention Study


1/22/2013 8:26:33 AM

Researchers have selected Eli Lilly and Co's experimental treatment, solanezumab, for a federally sponsored study of whether Alzheimer's disease can be slowed or prevented in older patients who have not yet developed significant memory problems. The closely watched "A4" prevention study will select 1,000 participants aged 70 to 85 who have varying levels in their brains of amyloid protein - believed to be a main cause of the memory-robbing disease. "This is the first time investigators will test an amyloid-clearing drug in older individuals thought to be in the pre-symptomatic stage of Alzheimer's disease," Brigham and Women's Hospital said on Friday. The affiliate of Harvard Medical School is helping coordinate the three-year study, which could cost up to $100 million. Solanezumab, a monoclonal antibody given by infusion, failed in two earlier Lilly-sponsored trials to slow the progression of the disease in patients who already had mild and moderate symptoms. But when data from the two large Phase III trials was combined and analyzed last summer, cognitive declines were slowed by 34 percent among patients who started out with only mild symptoms. It was the first time any drug ever arrested the progression of Alzheimer's. In the new prevention trial, patients will be selected by using a radioactive Lilly imaging agent called Amyvid (florbetapir) that can detect amyloid plaques in the brain. The agent is approved in the United States and was also approved in Europe this week. Dr. Reisa Sperling, a Harvard neurology professor who will lead the A4 trial, said she and her colleagues are hoping solanezumab will reduce memory decline by 30 percent. That would be similar to the benefit seen among already mildly symptomatic patients in Lilly's earlier pair of large studies.

Read at Reuters
Read at Motley Fool
Read at Seattle Times
 
 Read Article at  Related Companies  News Categories
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES